why the lack of interest?, page-3

I'm not sure why there's so little interest in Acrux - perhaps it's just that it has half as many shareholders as Alchemia and a quarter as many as Avexa.

Acrux is by far the least speculative of my speculative holdings. Actually, given the current climate, it's looking less risky than most of my blue chip holdings. It has enough cash to cover operating costs and product development for several years, a product (Evamist) in the market and a couple just waiting for registration (Ellavie and the Eli Lilly animal health product), and a long, wide, and rapidly moving product-pipeline.

Following the outstanding deal with KV and the relatively minor bad news with the loss of the Organon partnership, the share price has dropped from 1.27 to 0.57, albeit on very thin trading volumes. I've been accumulating all the way down.

With exchange rates where they are, a reasonable case could be made that Evamist and Ellavie alone underwrite the current share price. Personally, I wouldn't even consider a takeover offer under $5.